GLP-1 Receptor Agonists and Atrial Fibrillation Risk: A Meta-Analysis
This week, a comprehensive analysis published in Cureus examined whether glucagon-like peptide-1 (GLP-1) receptor agonists—medications widely used for type 2 diabetes and obesity—are associated with an increased risk of atrial ... Read More